Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

Blocking the immunoinhibitory PD-1:PD-L1 pathway using monoclonal antibodies has led to dramatic clinical responses by reversing tumor immune evasion and provoking robust and durable antitumor responses. Anti-PD-1 antibodies have now been approved for the treatment of melanoma, and are being clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Prodeus, Aaron, Abdul-Wahid, Aws, Fischer, Nicholas W., Huang, Eric H-B, Cydzik, Marzena, Gariépy, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417124/
https://www.ncbi.nlm.nih.gov/pubmed/25919090
http://dx.doi.org/10.1038/mtna.2015.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417124/
https://www.ncbi.nlm.nih.gov/pubmed/25919090
http://dx.doi.org/10.1038/mtna.2015.11

Ejemplares similares